Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Mutch

Showing results (31-40 of 84) with videos related to

Pageof 9
Sort By:
Gynecologic Oncology|June 12, 2022
Overall survival in patients with FIGO stage IVA cervical cancerJoshua P Schiff, Rachel Mintz, Alexander C Cohen, et al.
Plos One|May 2, 2015
Incorporation of porcine adenovirus 4 fiber protein enhances infectivity of adenovirus vector on dendritic cells: implications for immune-mediated cancer therapyIvy Wilkinson-Ryan, Julius Kim, Sojung Kim, et al.
Cancer|July 20, 2012
BRCA1, TP53, and CHEK2 germline mutations in uterine serous carcinomaKathryn P Pennington, Tom Walsh, Ming Lee, et al.
Gynecologic Oncology|July 7, 2015
Assessing the prognostic role of ATR mutation in endometrioid endometrial cancer: An NRG Oncology/Gynecologic Oncology Group studyIsrael Zighelboim, Shamshad Ali, Heather A Lankes, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 25, 2010
Activity of sorafenib in recurrent ovarian cancer and primary peritoneal carcinomatosis: a gynecologic oncology group trialDaniela Matei, Michael W Sill, Heather A Lankes, et al.
The Lancet. Oncology|December 25, 2012
Selumetinib in women with recurrent low-grade serous carcinoma of the ovary or peritoneum: an open-label, single-arm, phase 2 studyJohn Farley, William E Brady, Vinod Vathipadiekal, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|May 15, 2025
The new 2023 endometrial cancer FIGO staging system: balancing innovation with complexityEmilia Palmieri, Andrea Mariani, Robert Coleman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 26, 2023
A Phase II Basket Trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART SWOG 1609 Cohort 47) in Patients with Gestational Trophoblastic NeoplasiaSandip P Patel, Megan Othus, Young Kwang Chae, et al.
Journal of the National Cancer Institute|June 20, 2015
Relationships of Tubal Ligation to Endometrial Carcinoma Stage and Mortality in the NRG Oncology/ Gynecologic Oncology Group 210 TrialAshley S Felix, Louise A Brinton, D Scott McMeekin, et al.
Gynecologic Oncology|March 15, 2013
Etiologic heterogeneity in endometrial cancer: evidence from a Gynecologic Oncology Group trialLouise A Brinton, Ashley S Felix, D Scott McMeekin, et al.
Pageof 9

Showing results (31-40 of 84) with videos related to

Sort By:
Pageof 9
Gynecologic Oncology|June 12, 2022
Overall survival in patients with FIGO stage IVA cervical cancerJoshua P Schiff, Rachel Mintz, Alexander C Cohen, et al.
Plos One|May 2, 2015
Incorporation of porcine adenovirus 4 fiber protein enhances infectivity of adenovirus vector on dendritic cells: implications for immune-mediated cancer therapyIvy Wilkinson-Ryan, Julius Kim, Sojung Kim, et al.
Cancer|July 20, 2012
BRCA1, TP53, and CHEK2 germline mutations in uterine serous carcinomaKathryn P Pennington, Tom Walsh, Ming Lee, et al.
Gynecologic Oncology|July 7, 2015
Assessing the prognostic role of ATR mutation in endometrioid endometrial cancer: An NRG Oncology/Gynecologic Oncology Group studyIsrael Zighelboim, Shamshad Ali, Heather A Lankes, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 25, 2010
Activity of sorafenib in recurrent ovarian cancer and primary peritoneal carcinomatosis: a gynecologic oncology group trialDaniela Matei, Michael W Sill, Heather A Lankes, et al.
The Lancet. Oncology|December 25, 2012
Selumetinib in women with recurrent low-grade serous carcinoma of the ovary or peritoneum: an open-label, single-arm, phase 2 studyJohn Farley, William E Brady, Vinod Vathipadiekal, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|May 15, 2025
The new 2023 endometrial cancer FIGO staging system: balancing innovation with complexityEmilia Palmieri, Andrea Mariani, Robert Coleman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 26, 2023
A Phase II Basket Trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART SWOG 1609 Cohort 47) in Patients with Gestational Trophoblastic NeoplasiaSandip P Patel, Megan Othus, Young Kwang Chae, et al.
Journal of the National Cancer Institute|June 20, 2015
Relationships of Tubal Ligation to Endometrial Carcinoma Stage and Mortality in the NRG Oncology/ Gynecologic Oncology Group 210 TrialAshley S Felix, Louise A Brinton, D Scott McMeekin, et al.
Gynecologic Oncology|March 15, 2013
Etiologic heterogeneity in endometrial cancer: evidence from a Gynecologic Oncology Group trialLouise A Brinton, Ashley S Felix, D Scott McMeekin, et al.
Pageof 9